33
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Oroxylin-A Rescues LPS-Induced Acute Lung Injury via Regulation of NF-κB Signaling Pathway in Rodents

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background and Purpose

          Successful drug treatment for sepsis-related acute lung injury (ALI) remains a major clinical problem. This study was designed to assess the beneficial effects of post-treatment of oroxylin A (OroA), a flavonoid, in ameliorating lipopolysaccharides (LPS)-induced lung inflammation and fatality.

          Experimental Approach

          Rats were injected with LPS (10 mg/kg, iv) to induce ALI, and OroA was given (15 mg/kg, iv) 1 hr or 6 hrs after LPS challenge. Twenty four hrs after LPS challenge, biochemical changes in the blood and lung tissues, and morphological/histological alterations in the lung associated with inflammation and injury were examined. Therapeutic effect of OroA was assessed by measuring the survival rate in endotoxemic mice.

          Key Results

          LPS (10 mg/kg, iv) significantly altered WBC counts, elevated plasma tumor necrosis factor (TNF)-α and nitric oxide (NO), increased pulmonary edema, thickened alveolar septa, and decreased survival rate. These changes were ameliorated by OroA (15 mg/kg, iv) administered 1 hr or 6 hrs after LPS challenge. This post-treatment also significantly attenuated LPS-induced activation of nuclear factor-κB (NF-κB) and the release of high mobility group box 1 (HMGB1) in lung tissues. Furthermore, post-treatment with OroA (60 mg/kg, ip) administered 1 hr or 6 hrs after LPS challenge in mice significantly increased survival rate.

          Conclusion and Implication

          OroA administered after induction of ALI by LPS significantly prevent and revere lung tissues injuries with increased survival rate. Positive post-treatment effects of OroA suggest that OroA is a potentially useful candidate for managing lung inflammation in LPS-induced endotoxemia and septic shock.

          Related collections

          Most cited references41

          • Record: found
          • Abstract: found
          • Article: not found

          Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome.

          There is currently no optimal treatment or effective drug for severe acute respiratory syndrome (SARS), because the immunopathologic mechanism is poorly understood. To explore the immune mechanism underlying the pathogenesis of SARS, we studied the expression profile of cytokines/chemokines in the blood and the immunopathology of the lung and lymphoid tissues. Fourteen cytokines/chemokines in the blood of 23 patients with SARS were dynamically screened, using a bead-based multiassay system. Reverse transcription-polymerase chain reaction was performed to amplify mRNA. Histopathology of the lung and lymphoid tissues at autopsy was examined, using methods of immunohistochemistry and double immunofluorescence staining. Interferon-inducible protein-10 (IP-10) was markedly elevated in the blood during the early stage of SARS, and remained at a high level until convalescence. Moreover, IP-10 was highly expressed in both lung and lymphoid tissues, where monocyte-macrophage infiltration and depletion of lymphocytes were observed. The levels of interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 were concomitantly increased in the blood of the patients with superinfection, and the mRNAs for these cytokines were also increased in lung tissues. Induction of IP-10 is a critical event in the initiation of immune-mediated acute lung injury and lymphocyte apoptosis during the development of SARS. Superinfection after the immune injury is the main cause of death. The prompt elevation of interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 is a sign of superinfection, indicating a high risk of death.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Regulation of endothelial junctional permeability.

            The endothelium is a semi-permeable barrier that regulates the flux of liquid and solutes, including plasma proteins, between the blood and surrounding tissue. The permeability of the vascular barrier can be modified in response to specific stimuli acting on endothelial cells. Transport across the endothelium can occur via two different pathways: through the endothelial cell (transcellular) or between adjacent cells, through interendothelial junctions (paracellular). This review focuses on the regulation of the paracellular pathway. The paracellular pathway is composed of adhesive junctions between endothelial cells, both tight junctions and adherens junctions. The actin cytoskeleton is bound to each junction and controls the integrity of each through actin remodeling. These interendothelial junctions can be disassembled or assembled to either increase or decrease paracellular permeability. Mediators, such as thrombin, TNF-alpha, and LPS, stimulate their respective receptor on endothelial cells to initiate signaling that increases cytosolic Ca2+ and activates myosin light chain kinase (MLCK), as well as monomeric GTPases RhoA, Rac1, and Cdc42. Ca2+ activation of MLCK and RhoA disrupts junctions, whereas Rac1 and Cdc42 promote junctional assembly. Increased endothelial permeability can be reversed with "barrier stabilizing agents," such as sphingosine-1-phosphate and cyclic adenosine monophosphate (cAMP). This review provides an overview of the mechanisms that regulate paracellular permeability.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The cytokine activity of HMGB1.

              High mobility group box 1 (HMGB1) is a highly conserved, ubiquitous protein present in the nuclei and cytoplasm of nearly all cell types. We recently discovered that HMGB1 is secreted into the extracellular milieu and acts as a proinflammatory cytokine. Administration of HMGB1 to normal animals causes inflammatory responses, including fever, weight loss and anorexia, acute lung injury, epithelial barrier dysfunction, arthritis, and death. Anti-HMGB1 treatment, with antibodies or specific antagonists, rescues mice from lethal endotoxemia or sepsis and ameliorates the severity of collagen-induced arthritis and endotoxin-induced lung injury. Here, we give an abridged review of the cytokine activity of HMGB1, its secretion and release into the extracellular milieu, the putative signal transduction pathways, including interaction with cell-surface receptors and intracellular signaling, and its role in several inflammatory diseases. Finally, the therapeutic potential of blocking HMGB1 in the treatment of inflammatory diseases is discussed.
                Bookmark

                Author and article information

                Contributors
                Role: Editor
                Journal
                PLoS One
                PLoS ONE
                plos
                plosone
                PLoS ONE
                Public Library of Science (San Francisco, USA )
                1932-6203
                2012
                10 October 2012
                : 7
                : 10
                : e47403
                Affiliations
                [1 ]Institute of Medical Sciences, Tzu-Chi University, Hualien, Taiwan
                [2 ]Institute of Pharmacology and Toxicology, Tzu-Chi University, Hualien, Taiwan
                [3 ]Department of Life Science, Tzu-Chi University, Hualien, Taiwan
                [4 ]Center of Vascular Medicine, College of Life Science, Tzu-Chi University, Hualien, Taiwan
                [5 ]Department of Pathology, College of Medicine, Tzu-Chi University, Hualien, Taiwan
                [6 ]Department of Research, Buddhist Tzu-Chi General Hospital, Hualien, Taiwan
                [7 ]Department of Emergency Medicine, Buddhist Tzu-Chi General Hospital, Hualien, Taiwan
                [8 ]Tzu-Chi College of Technology, Hualien, Taiwan
                [9 ]Department of Chemistry, National Dong Hwa University, Hualien, Taiwan
                [10 ]Department of Pharmacology, Southern Illinois University School of Medicine, Springfield, Illinois, United States of America
                Johns Hopkins School of Medicine, United States of America
                Author notes

                Competing Interests: The authors have declared that no competing interests exist.

                Conceived and designed the experiments: TLT MFC CPC TJFL. Performed the experiments: TLT. Analyzed the data: MJT TLT MFC YHH. Contributed reagents/materials/analysis tools: MFC CPC TJFL MJT. Wrote the paper: TLT.

                Article
                PONE-D-12-07559
                10.1371/journal.pone.0047403
                3468516
                23071799
                1ba6e79b-27b1-4cea-9135-5705234d1484
                Copyright @ 2012

                This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

                History
                : 15 March 2012
                : 14 September 2012
                Page count
                Pages: 11
                Funding
                Tzu-Chi University Grants TCMRC-C95005-01, TCRPP99006, TCIRP 98005-01 and TCIRP 98005-02, and National Science Council of Taiwan Grants NSC-NSC-95-2320-B-320-013-MY2, NSC-96-2320-B-320-005-MY3 and NSC 100-2320-B-320-007-MY2, Buddhist Tzu Chi General Hospital Grant TCRD98-34, and the Tzu Chi Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
                Categories
                Research Article
                Biology
                Biochemistry
                Drug Discovery
                Biotechnology
                Drug Discovery
                Immunology
                Immunity
                Inflammation
                Innate Immunity
                Medicine
                Clinical Immunology
                Immunity
                Inflammation
                Innate Immunity
                Critical Care and Emergency Medicine
                Sepsis
                Drugs and Devices
                Drug Research and Development
                Drug Discovery

                Uncategorized
                Uncategorized

                Comments

                Comment on this article